Citations

Clear

11 citation(s) found for "Han, Bing".

Chronic Cellular NAD Depletion Activates a Viral Infection‐Like Interferon Response Through Mitochondrial DNA Leakage
Chini, Claudia C.S. , Colman, Laura , Palmieri, Eduardo, Strange, Jessica L., Kashyap, Sonu , Benítez-Rosendo, Andrés, Lopez, Gina L. Ciccio, Rabelo, Sara Peixoto , Mukherjee, Shreyartha, Souza, Gustavo Henrique de , Varga, John , Meyer, Ralph G. , Meyer‐Ficca, Mirella L. , Chini, Eduardo N. , Mukherjee, Shreyartha , de Souza, Gustavo H, Chini, Eduardo Nunes , Palmieri, Eduardo, Han, Bing , Lopez, Gina L. Ciccio, Mukherjee, Shreyartha, Mukherjee, Shreyartha

Mayo Clinic

Aging Cell | June 16, 2025 | Volume: 24 | Issue: 9 | Pages: No page available

10.1111/acel.70135 | PMID 40519092 Get It

ABSTRACT Nicotinamide adenine dinucleotide (NAD) is a key coenzyme involved in energy metabolism, DNA repair, and cellular signaling. While the effects of acute NAD depletion have been better characterized, the consequences of chronic NAD deficiency remain unclear. Here, we investigated the impact of chronic NAD depletion in cultured cells by removing the availability of nicotinamide (NAM), a key precursor for NAD synthesis, from the culture media. In NIH3T3 fibroblasts, NAM depletion caused a dramatic drop in intracellular NAD levels within 2 days. Remarkably, the cells remained viable even after 7–14 days of NAM depletion, despite NAD + levels falling to less than 10% of control conditions. This chronic NAD depletion led to distinct metabolic alterations. Mitochondrial basal respiration remained unchanged, but cells exhibited reduced spare respiratory and maximal capacities, along with significantly impaired glycolysis. Notably, NAD depletion triggered an interferon‐dependent inflammatory response, resembling viral infections. This was driven by cytosolic leakage of mitochondrial DNA (mtDNA) through voltage‐dependent anion channel 1 (VDAC1), which activated the cGAS‐STING signaling pathway. Inhibition of VDAC oligomerization with VBIT‐4, STING signaling with H‐151, or mtDNA depletion blocked the upregulation of interferon genes induced by NAM depletion. Similar interferon responses triggered by NAD depletion were observed in IMR90 human fibroblasts and HS5 stromal cells. Our findings reveal a novel link between chronic NAD deficiency, VDAC‐mediated mtDNA release to the cytoplasm, and the activation of the inflammatory response, providing new insight into how NAD decline affects cellular metabolic and inflammatory processes.
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
Parrondo, Ricardo , Dutta, Navnita , LaPlant, Betsy, Elliott, Jamie, Fernandez, Andre, Zimmerman, Ashley, Cicco, Gina, Han, Bing , Heslop, Keisha, Chapin, Dustin, Sher, Taimur , Rasheed, Ahsan , Das, Saurav , Chanan‐Khan, Asher , Paulus, Aneel , Parrondo, Ricardo D , LaPlant, Betsy R, Das, Saurav , Chanan-Khan, Asher , Ailawadhi, Sikander , Paulus, Aneel , Cicco, Gina, Roy, Vivek , Ailawadhi, Sikander

Mayo Clinic

British Journal of Haematology | January 30, 2024 | Volume: 204 | Issue: 5 | Pages: 1825-1829

10.1111/bjh.19320 | PMID 38286472 Get It

SummaryThis phase II study evaluated time‐limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow‐up time of 25.7 months, the median progression‐free survival (PFS) was 22.9 months. While the primary end‐point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Dutta, Navnita , Han, Bing , Ciccio, Gina , Cherukuri, Yesesri , Alegria, Victoria R., LaPlant, Betsy, Sher, Taimur , Lanier, Stephanie, Manna, Alak , Heslop, Keisha, Caulfield, Thomas R. , Maldosevic, Emir , Störz, Peter , Asmann, Yan W. , Chanan‐Khan, Asher , Paulus, Aneel , Dutta, Navnita , Han, Bing , LaPlant, Betsy R, Edwards, Brett , Caulfield, Thomas R , Storz, Peter , Asmann, Yan, Chanan-Khan, Asher A., Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek , Edwards, Brett, Manochakian, Rami

Mayo Clinic

Cancers | January 12, 2023 | Volume: 15 | Issue: 2 | Pages: 477

10.3390/cancers15020477 | PMID 36672426 Get It

Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces apoptosis in MM cells. When combined with lenalidomide and dexamethasone (Rd), AT-101 significantly reduced tumor burden in an in vivo xenograft model of MM. These data provided rationale for a phase I/II study to establish the effective dose of AT-101 in combination with Rd (ARd regimen) in relapsed/refractory MM. A total of 10 patients were enrolled, most with high-risk cytogenetics (80%) and prior stem cell transplant (70%). Three patients were lenalidomide-refractory, 2 were bortezomib-refractory and 3 were daratumumab-refractory. The ARd combination was well tolerated with most common grade 3/4 adverse events being cytopenia’s. The overall response rate was 40% and clinical benefit rate was 90%. The median progression free survival was 14.9 months (95% CI 7.1-NE). Patients responsive to ARd showed a decrease in Bcl-2:Bim or Mcl-1:Noxa protein complexes, increased CD8+ T and NK cells and depletion of T and B-regulatory cells. The ARd regimen demonstrated an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM prompting further investigation in additional patients.
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Deng, Jing , Paulus, Aneel , Fang, Douglas D. , Manna, Alak , Wang, Guangfeng , Wang, Hengbang , Zhu, Saijie , Chen, Jianyong , Min, Ping , Yin, Yan , Dutta, Navnita , Halder, Nabanita , Ciccio, Gina , Copland, John A. , Miller, James L. , Han, Bing , Bai, Longchuan , Liu, Liu , Wang, Mi , McEachern, Donna , Przybranowski, Sally , Yang, Chao‐Yie , Stuckey, Jeanne A. , Li, Caixia , Letai, Anthony , Yang, Dajun , Wang, Shaomeng , Chanan‐Khan, Asher , Miller, James , Wu, Depei , Li, Caixia , Ryan, Jeremy , Letai, Anthony , Ailawadhi, Sikander , Yang, Dajun , Wang, Shaomeng , Chanan-Khan, Asher , Zhai, Yifan , Paulus, Aneel , Ryan, Jeremy , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 24 | Pages: 5455-5468

10.1158/1078-0432.ccr-21-4037 | PMID 36048524 Get It

Abstract Purpose: Development of B-cell lymphoma 2 (BCL-2)–specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein–protein interactions. We report herein discovery and extensive preclinical investigation of lisaftoclax (APG-2575). Experimental Design: Computational modeling was used to design “lead” compounds. Biochemical binding, mitochondrial BH3 profiling, and cell-based viability or apoptosis assays were used to determine the selectivity and potency of BCL-2 inhibitor lisaftoclax. The antitumor effects of lisaftoclax were also evaluated in several xenograft models. Results: Lisaftoclax selectively binds BCL-2 (Ki < 0.1 nmol/L), disrupts BCL-2:BIM complexes, and compromises mitochondrial outer membrane potential, culminating in BAX/BAK-dependent, caspase-mediated apoptosis. Lisaftoclax exerted strong antitumor activity in hematologic cancer cell lines and tumor cells from patients with chronic lymphocytic leukemia, multiple myeloma, or Waldenström macroglobulinemia. After lisaftoclax treatment, prodeath proteins BCL-2‒like protein 11 (BIM) and Noxa increased, and BIM translocated from cytosol to mitochondria. Consistent with these apoptotic activities, lisaftoclax entered malignant cells rapidly, reached plateau in 2 hours, and significantly downregulated mitochondrial respiratory function and ATP production. Furthermore, lisaftoclax inhibited tumor growth in xenograft models, correlating with caspase activation, poly (ADP-ribose) polymerase 1 cleavage, and pharmacokinetics of the compound. Lisaftoclax combined with rituximab or bendamustine/rituximab enhanced antitumor activity in vivo. Conclusions: These findings demonstrate that lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2–selective inhibitor with considerable potential for the treatment of certain hematologic malignancies.
OR21-1 Adiposity and Diabetes Genetic Risk Modulates Causal Effects of BMI and Type 2 Diabetes on NAFLD: A Wax-and-Wane Pattern
Wang, Yuying , Chen, Yi , Xia, Fangzhen , Han, Bing , Li, Qin , Jensen, Michael D. , Lu, Yingli , Wang, Ningjian , Wan, Heng , Chen, Chi , Zhang, Wen

Mayo Clinic

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-or21-1 Get It

Adiposity Genetic Risk Score Modifies the Association Between Blood Lead Level and Body Mass Index
Wang, Ningjian , Lu, Meng , Chen, Chi , Xia, Fangzhen , Han, Bing , Cheng, Jing , Jensen, Michael D. , Lu, Yingli , Li, Qin , Chen, Yi , Zhu, Chunfang

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 7, 2018 | Volume: 103 | Issue: 11 | Pages: 4005-4013

10.1210/jc.2018-00472 | PMID 30202913 Get It

Abstract Context Previous epidemiological studies had inconsistent results regarding the relationship between blood lead level (BLL) and adiposity. Objective We aimed to investigate the associations of BLL with body mass index (BMI) particularly using Mendelian randomization analyses and examine the interaction between obesity-predisposing genes and BLL on the associations. Design and Setting A total of 3922 participants were enrolled from 16 sites in East China in 2014 from the Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (ChiCTR-ECS-14005052, www.chictr.org.cn). We calculated the weighted BMI genetic risk score (GRS) based on 29 variants that were identified and validated in East Asians. BLL was measured by atomic absorption spectrometry. Main Outcome Measure BMI was calculated, and BMI ≥25 kg/m2 was defined as overweight. Results Multivariable logistic regression analysis demonstrated significant associations between BMI with each unit increase in lnBLL (β = 0.24; 95% CI, 0.08 to 0.40; P < 0.001) and each 1-point increase in BMI-GRS (β = 0.08; 95% CI, 0.05 to 0.11; P < 0.001). The causal regression coefficients of genetically determined BMI for lnBLL were −0.003 (95% CI, −0.075 to 0.070), which showed no significance. The GRS modified the association of BLL with BMI and overweight (BMI ≥25 kg/m2; P for interaction = 0.031 and 0.001, respectively). Each unit of lnBLL was associated with 63% higher odds of overweight (OR 1.63; 95% CI, 1.30 to 2.05) in the highest quartile of GRS, but no significant associations were found in the lower three quartiles. Conclusions The associations of BLL with BMI and overweight (BMI ≥25 kg/m2) were significantly modulated by BMI genetic susceptibility.
Testosterone: Relationships with Metabolic Disorders in Men—An Observational Study from SPECT-China
Cheng, Jing , Han, Bing , Qin, Li , Xia, Fangzhen , Zhai, Hualing, Wang, Ningjian , Jensen, Michael D. , Lu, Yingli , Jensen, Michael

Mayo Clinic

International Journal of Endocrinology | December 3, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-8

10.1155/2017/4547658 | PMID 29333158 Get It

Background. The strength of associations between total testosterone (TT) and metabolic parameters may vary in different nature of population structure; however, no study has ever given this information in Chinese population, especially those without metabolic syndrome (MS). We aimed to analyze the association magnitudes between TT and multiple metabolic parameters in general Chinese men. Methods. 4309 men were recruited from SPECT-China study in 2014-2015, which was performed in 22 sites in East China. TT, weight status, and various metabolic parameters were measured. Linear and logistic regressions were used to analyze the associations. Results. Men in lower TT quartiles had worse metabolic parameters including body mass index, triglycerides, HbA1c, and HOMA-IR (all P for trend < 0.001). Body mass index (B −0.32, 95%CI −0.35 to −0.29) and obesity (OR 0.40, 95%CI 0.35–0.45) had the largest association magnitude per one SD increment in TT, while blood pressure and hypertension (OR 0.90, 95%CI 0.84–0.98) had the smallest. These associations also persisted in individuals without metabolic syndrome. Conclusions. Obesity indices had closer relationships with TT than most other metabolic measures with blood pressure the least close. These associations remained robust after adjustment for adiposity and in subjects without metabolic syndrome.
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression
Shen, Yihang , Zhang, Piyan , Panneerselvam, Jayabal, Che, Raymond , Fei, Peiwen, Han, Bing , Zhang, Jun , Yu, Kai

Mayo Clinic

Oncotarget | February 3, 2017 | Volume: 8 | Issue: 14 | Pages: 22490-22500

10.18632/oncotarget.14989 | PMID 28157704 Get It

Is Exposure to Famine in Childhood and Economic Development in Adulthood Associated With Diabetes?
Wang, Ningjian , Wang, Xiaojin , Han, Bing , Li, Qin , Chen, Yi , Chen, Yingchao , Xia, Fangzhen , Cang, Zhen, Zhu, Chaoxia , Lu, Meng , Lin, Dongping, Wang, Bingshun , Jensen, Michael D. , Lu, Yingli , Zhu, Chunfang, Meng, Ying , Chen, Chi , Zhu, Chunfang , Meng, Ying

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 28, 2015 | Volume: 100 | Issue: 12 | Pages: 4514-4523

10.1210/jc.2015-2750 | PMID 26509871 Get It

Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate
Panneerselvam, Jayabal, Pickering, Anna, Li, Liantao , Zheng, Junnian , Zhang, Yanbin , Fei, Peiwen, Han, Bing , Zhang, Jun

Mayo Clinic

Oncotarget | September 16, 2015 | Volume: 5 | Issue: 5 | Pages: 1326-1337

10.18632/oncotarget.1796 | PMID 24658369 Get It